MOTS-c vs Semax
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
MOTS-c
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that plays a key role in metabolic regulation and has emerged as a significant longevity research target.
Full details →Semax
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.
Full details →Side-by-Side Comparison
| Aspect | MOTS-c | Semax |
|---|---|---|
| Dose Range | 5 mg–10 mg | 300 mcg–600 mcg |
| Frequency | Less than daily | 2x daily |
| Cycle Length | 8–12 weeks | 2–4 weeks |
| Route | subcutaneous | intranasal |
| Mechanism | Activates AMPK pathway, enhances glucose uptake in skeletal muscle, improves insulin sensitivity, and regulates mitochondrial function. Acts as a metabolic hormone affecting whole-body energy homeostasis. | Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning. |
| Typical Dosage | Research protocols typically use 5-10mg administered subcutaneously several times per week. Optimal dosing not yet established. | Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery. |
| Administration | Subcutaneous injection. Often combined with exercise protocols as it enhances exercise capacity and metabolic adaptation. | Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency. |
| Side Effects | Limited human data. Animal studies show good tolerability. May affect energy levels and exercise performance. | Generally well-tolerated. May cause mild irritability or hair shedding in some users. |
| Best For |
Key Differences
Unique to MOTS-c:
Unique to Semax:
Key Studies
MOTS-c
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.
Free radical biology & medicine, 2026
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.
Redox biology, 2025
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy?
Cardiovascular drugs and therapy, 2025
Semax
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.
British journal of pharmacology, 2025
- The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease.
Acta naturae, 2025
- The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain Neurons.
Bulletin of experimental biology and medicine, 2025
Ready to Learn More?
Looking for trusted sources?